Connect with us

Cancer

Menopause drug may reduce breast cancer growth in postmenopausal women, study finds

Published

on

A menopause drug commonly used to relieve symptoms such as hot flushes may also help slow the growth of breast cancer cells in postmenopausal women, according to new clinical trial results.

The phase two trial, led by researchers at Northwestern University, found that Duavee—a medication prescribed for menopause-related symptoms—appeared to reduce cell growth in the breast tissue of women diagnosed with ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer that remains within the milk ducts.

Almost 60,000 women are diagnosed with DCIS each year. While the condition is not invasive, it can indicate a higher risk of developing invasive tumours later in life.

In the study, 141 postmenopausal women with DCIS were recruited. Half received Duavee and the other half were given a placebo for the month between diagnosis and breast cancer surgery.

DCIS is most often detected during routine mammograms, makes up around 25 per cent of all breast cancer diagnoses, and has a 98 per cent recovery rate at 10 years when removed by surgery.

To reduce the risk of recurrence, many patients also undergo treatments such as radiation or hormone therapy following surgery—both of which can lead to significant side effects.

Duavee is a combination of oestrogen and bazedoxifene, a selective oestrogen receptor modulator (SERM) that either enhances or blocks the effects of oestrogen depending on the type of tissue. It is also used to treat osteoporosis.

Those who took Duavee showed notably less cell growth in their breast tissue by the time of surgery, and researchers reported “no impact on quality of life compared to placebo.”

Dr Swati Kulkarni is a surgeon at Northwestern University and lead investigator of the trial.

Kulkarni said: “What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer.

Importantly, participants taking Duavee did not experience the intolerable side effects often associated with cancer drugs.

Instead, the medication tended to improve quality of life in women already dealing with menopause symptoms such as night sweats and hot flushes.

Although larger studies are still needed to confirm whether Duavee can prevent invasive breast cancer, the researchers suggest that it could offer benefits to women with an elevated risk of breast cancer who also suffer from menopause-related symptoms.

This is especially significant because women with a history of cancer lesions are typically advised not to use hormone replacement therapy to relieve menopause symptoms, due to the potential risk of cancer returning.

The researchers concluded: “These results support consideration that Duavee is a safe option to manage menopausal symptoms for women concerned about their risk of developing breast cancer.

“They also provide supportive evidence that Duavee may reduce the risk of developing invasive breast cancer.”

The trial results have not yet been published in a peer-reviewed journal but were presented at the American Society of Clinical Oncology’s latest annual meeting.

Insight

AI cuts interval breast cancers in Swedish trial

Published

on

An AI tool cut interval breast cancers by 12 per cent in a Swedish screening trial of more than 105,000 women.

The study also found 27 per cent fewer aggressive breast cancers detected at screening when AI was used.

Interval cancers are cancers found between routine screening appointments because they were missed at the original scan. They are often more dangerous and linked to higher death rates than cancers found at screening.

The MASAI trial is described as the first large randomised study to test whether AI can improve mammography screening, which uses low-dose X-rays to examine breast tissue for signs of cancer.

The AI tool, called Transpara Detection and developed by ScreenPoint Medical, supported radiologists in analysing mammography images.

Earlier results from the same trial showed that Transpara Detection increased cancers found by 29 per cent and reduced radiologist workload by 44 per cent compared with standard double-reading, where two radiologists independently review each scan.

The latest findings indicate higher accuracy with AI support. Sensitivity, the ability to detect cancer, was 6.7 percentage points higher in the AI group while specificity, the ability to rule out healthy cases, was maintained. Results were similar across age groups and breast density levels.

Women screened with AI had 16 per cent fewer invasive interval cancers and 21 per cent fewer large interval cancers than those in the standard screening group.

The system also helps doctors assess risk more precisely by subdividing suspicious findings into BI-RADS 4 categories A, B and C. BI-RADS (Breast Imaging Reporting and Data System) is a standardised scale that guides whether a patient needs closer monitoring, further tests or treatment.

Continue Reading

Wellness

Study links changing population to low London screening rates

Published

on

London’s shifting population is holding down breast screening uptake, experts have said, with the capital at 62.8 per cent in 2024, below the NHS’s acceptable 70 per cent threshold.

The London Assembly Health Committee recently heard that the capital faces distinct challenges compared with the rest of the country and that these issues must be addressed.

Josephine Ruwende, a cancer screening lead at NHS England, said frequent moves within the rented sector and the cost-of-living crisis pushing people out of London had made it difficult to reach eligible patients, which she described as “population churn”.

She said: “This is people changing addresses and then not updating their GP, this then affects the invitation process because GP details are used to identify individuals who are eligible.

“In boroughs where we have the highest population churn, we see it strongly associated with lower uptake.”

She noted that even in the wealthiest boroughs there can be high levels of movement, with around 40 per cent of residents changing address within a year.

Such areas also tend to have more people who own second homes or spend long periods abroad, making it harder for the NHS to keep contact details up to date.

As a result, screening invitations may be sent to out-of-date addresses or to people who are overseas.

Leeane Graham, advocacy lead at Black Women Rising, which supports women of colour with a cancer diagnosis, said there were cultural barriers, fear and a mistrust of the health service due to previous experience within communities.

She said: “If you’ve never been for a breast screening before, the thought of having a mammogram can be really, really terrifying.”

Helen Dickens, from Breast Cancer Now, said other reasons included a lack of understanding of breast screening, along with concerns about discomfort, trust and practical issues such as travel.

She said: “We have amazing public transport and we feel that we’ve got great accessibility, but we also know that we don’t have screening centres in every borough.

“We know that for some women that barrier of transport and access will still be a really big reason why they’re not attending screenings.”

NHS London launched its first screening campaign last year in response to the figures, aiming to increase detection at an earlier stage.

Continue Reading

Insight

Period blood screening could boost cervical cancer checks

Published

on

Testing period blood for signs of cervical cancer could offer an accurate, convenient screening option for women who avoid clinic appointments, researchers say.

The current NHS test involves a nurse or doctor taking cells from the cervix, yet a third of those invited do not attend.

A study of the new test, which can be done at home, used blood collected on a cotton strip attached to a standard sanitary pad.

In research involving more than 3,000 women aged 20 to 54 years, Chinese investigators compared testing period blood collected on mini-pads with samples taken by clinicians.

Results were shared via a dedicated app.

When analysed in the lab, blood testing was nearly as good at identifying people with disease as other methods, and very good at ruling out those without it.

Cervical screening appointments are offered to all women, and anyone with a cervix, every five years between ages 25 and 64 in the UK.

Screening looks for high-risk human papillomavirus, a virus that can cause cancer.

A nurse or doctor carries out the test using a speculum to access the cervix.

However, five million women are not up to date, for reasons including fear, pain and discomfort.

“Cervical screening can be difficult for some women for many reasons, like if they have had a bad previous experience, they are menopausal, they have a physical or learning disability, cultural barriers, or are a survivor of sexual violence,” said Athena Lamnisos from charity The Eve Appeal.

Younger women, those with disabilities, and people from ethnic minority communities and LGBT+ groups are more likely to miss appointments.

Researchers say using menstrual blood for HPV testing is convenient, respects privacy and reduces discomfort.

Anyone who tests positive for HPV would be sent for a colposcopy, a close examination of the cervix with a magnifying instrument to look for pre-cancerous cells.

Experts caution that period blood tests are not an immediate alternative to current screening because only women who menstruate could use them.

Some also note the study may have overestimated performance because not all participants had a biopsy to double check results.

Sophie Brooks, health information manager at Cancer Research UK, said it was encouraging to see research exploring new ways to make screening more accessible.

She said testing menstrual blood for HPV was an interesting, non-invasive approach but more research in diverse groups is needed to see how it could fit into existing programmes.

Athena Lamnisos added that it was exciting to see more acceptable ways of offering a potentially life-saving test.

“People have different barriers and concerns about screening, so being able to offer a choice of different methods could be very positive for some who are eligible for screening but don’t currently attend,” she said.

The NHS is already sending at-home test kits to women in some areas of England who have missed several screening appointments.

These DIY kits, containing a vaginal swab, will be sent out more widely at some point this year.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.